Epitalon: What Lakeland Readers Should Know

Epitalon is a small lab-made peptide promoted online as an anti-aging or “longevity” treatment. Most of what is known about it comes from lab dishes, animals and one research network in Russia. This page explains what the research does and does not show, and where its regulatory status stands. It is general information, not advice for your situation.

What it is and how it works

Epitalon is a chain of four amino acids: alanine, glutamic acid, aspartic acid and glycine (Ala-Glu-Asp-Gly). It was designed from the makeup of epithalamin, an extract from cattle pineal glands. FDA treats epitalon and epithalamin as different substances.¹

It was created by Professor Vladimir Khavinson’s group in St. Petersburg, Russia. FDA notes that most studies of how epitalon works have come from that group.¹

The main claim is about telomeres, the protective caps on the ends of chromosomes that shorten as cells divide. In 2003, Khavinson’s group reported that epitalon switched on telomerase, an enzyme that rebuilds telomeres, and lengthened telomeres in human cells grown in a dish.² These are cell-culture results.

What the research shows (and where evidence is weak)

Lab studies. A 2025 lab study outside the original group reported telomere lengthening in normal human cells. It also reported lengthening in breast cancer cells, by a different mechanism.³ That study later published a correction that replaced its first three figures.⁴⁵ One study is not enough to confirm the effect, and nothing shows it happens in the human body.

Animal studies. In the key mouse lifespan study, epitalon did not change average lifespan. The longest-lived 10% of mice lived about 13% longer.⁶ FDA criticized this work: it used one fixed dose, only female mice and a short exposure.¹

Human studies of epitalon itself. FDA found only three:¹

• Two studies in night-shift workers, given epitalon under the tongue. The main one randomized 40 women aged 40 to 50 to epitalon or placebo for 20 days. A breakdown product of melatonin in urine rose 1.7-fold. The study did not say whether it was blinded, did not measure sleep and did not report safety. The second study appears to have used an overlapping group of people.¹⁵
• One 2002 study in 162 people with retinitis pigmentosa, an inherited eye disease, using injections near the eye. It had no placebo group, and how patients were assigned and whether the study was blinded were unclear.⁵ Epitalon received a U.S. orphan-drug designation for this disease in 2010. That designation was withdrawn in 2016.¹

FDA found no studies in people with insomnia and none using injections under the skin, the way it is usually sold.¹

A common mix-up. Human “lower death rate” numbers quoted online come from studies of epithalamin, sometimes combined with another extract, from the same research network. They are not studies of epitalon.⁵

Overall. An independent 2026 review concluded epitalon is “biologically active but clinically unproven.” No adequately powered randomized trial has shown it works for any condition.⁵

FDA and regulatory status

Epitalon is not FDA-approved. It is not part of any approved drug. As of FDA’s May 2026 review, no approved epitalon product existed in the EU, the UK, Canada, Australia or several other countries.¹

Compounding. Epitalon was once on FDA’s “Category 2” list of compounding ingredients with possible significant safety risks. By April 22, 2026, the nominations had been withdrawn; FDA still lists its safety concerns.⁷ In a review dated May 12, 2026, FDA’s scientists looked at epitalon for insomnia. They found no evidence it works and no clinical safety data, and recommended against adding it to the list of ingredients pharmacies may use.¹

An FDA advisory committee narrowly voted in July 2026 to recommend adding epitalon. The vote was reported as 7–4 with 1 abstention.⁸ FDA’s own reviewers had recommended against it, and the vote is not binding. As of November 2026, FDA’s meeting page posted no minutes or final decision.⁹

The 2026 HHS draft policy. As of November 13, 2026, HHS has published a draft, non-binding policy saying it does not intend to take enforcement action against licensed pharmacies compounding certain peptides in certain forms. This is not FDA approval, and FDA has not added these peptides to its official list.¹⁰ According to law-firm summaries of the draft policy, epitalon is one of six peptides it covers, limited to certain injectable forms and subject to conditions such as a single active ingredient and a patient-specific prescription.¹¹¹² The public comment period was set to close at the end of November 13, 2026.¹³ As of November 13, 2026, a final policy had not been published. Check the Federal Register notice for updates.¹⁰

Sports. Epitalon is likely covered by WADA’s ban on substances with no government approval for human use.¹⁴ Athletes should check with their anti-doping organization.

See our guides to compounded vs. FDA-approved peptides, whether peptides are legal in Florida and research chemical peptide risks.

Common side effects and safety

• No safety studies. FDA found no clinical studies of epitalon’s safety in people and no data on how the body absorbs or clears it. FDA’s adverse-event database had no reports through December 2025. A lack of reports is a lack of information, not proof of safety.¹
• Missing animal testing. FDA found no repeat-dose, reproductive or long-term cancer studies.¹
• A theoretical cancer concern. FDA said that, in theory, epitalon could promote cancer. Turning on telomerase and lengthening telomeres could help cells keep dividing when they should stop. This is a concern, not an observed harm, and it has not been studied properly.¹ The 2025 lab study saw telomere lengthening in cancer cells too.³
• Product quality. FDA found that quality documents for nominated epitalon lacked basic tests for bacterial toxins (endotoxin) and impurities. Clumps and impurities in injected peptides can trigger immune reactions.¹

Typical cost range

There is no approved product and no official price. FDA found it sold online as vials, capsules and sprays, many labeled “research use only.”¹ We did not find reliable price data. Ask any provider for a written price breakdown before you start.

See our cost guide for questions to ask about fees.

Questions to ask a provider

• What human evidence supports epitalon for my goal, and was it tested the way you plan to give it?
• How do you account for FDA’s theoretical cancer concern?
• Where does the product come from, and does the pharmacy test it for purity and bacterial toxins?
• How does the HHS draft policy apply to what you are offering, and what happens if it changes?
• Are there proven ways to address my sleep or aging concerns that we should try first?

For related topics, see the anti-aging goal page and the sleep goal page.